Prostate Cancer: C90203 (Iowa Cancer Specialists)

CTSU C90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

Objective

The purpose of this study is to compare the effects (good and bad) of the combination of chemotherapy and hormone therapy followed by radical prostatectomy (surgery to remove your prostate) with radical prostatectomy alone on patients with prostate cancer at high-risk of cancer recurrence after surgery to see which is better. The usual approach for treating prostate cancer is surgery alone.

This research is being done because many men with prostate cancer are at risk of having the cancer come back if they are treated only with surgery. We are trying to find out if giving chemotherapy with hormone therapy before surgery makes the chance of being cured of prostate cancer better.

The study will also examine whether anything in patients' diet or lifestyle predict how well they do overall with their cancer.

Click here for more information from the National Cancer Institute.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Prostate Cancer
Sponsor(s)
Cancer Trials Support Unit
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email